New Resource: Biosimilar Substitution State Statute Report

  • This page as PDF

Summary

Avalere’s report, available now, offers insights into state policies on point-of-service substitution of biosimilar products.

Request more information on the report’s contents, price, and purchase options.

In today’s rapidly evolving healthcare landscape, biosimilars have emerged as an option to address the demand for cost-effective and high-quality treatment options. A biosimilar is a type of biological product that shows no clinically meaningful differences from a reference Food and Drug Administration (FDA)-approved biological product. As with generic drugs, biosimilars are a subsequently approved version of the reference product and can be a clinically appropriate and less expensive option for patients. Even though there are similarities, generics are not the same as biosimilars: While both are lower-cost alternatives to brand drugs, biosimilars may not be chemically identical to their reference compound, unlike generics.

However, the complexities of biosimilar substitution statutes remain a challenge for prescribers, pharmacists, payers, and manufacturers. Avalere experts have created a comprehensive Biosimilar Substitution Statute Report, for manufacturers, providers, health plans, and patient advocates that offers guidance on the steps to substitution that may impact provider prescribing, pharmacy dispensing, and patient access.

What Is in the Report?

This report provides a comprehensive summary of state statutes on the substitution of interchangeable biosimilars for their reference biologic products. Publicly available information current as of January 25, 2024, was used to review and analyze statutes in all 50 states, the District of Columbia, and Puerto Rico that apply to the process for substitution. It highlights how these statutes can vary, detailing who is authorized to make the substitution, the circumstances under which a substitution may occur, and requirements for notification and permission.

The Biosimilar Substitution Statute Report answers key questions, including:

This report is not an interpretation of individual product interchangeability, as designated by the FDA, nor is it a recommendation for substitution or a guarantee of insurance coverage. It does not constitute legal advice or opinion; rather, it is for general informational purposes only. Until the FDA designates a biosimilar as “interchangeable,” any state statute regarding substitution based on interchangeability by a pharmacist does not yet apply. However, this report can serve as an educational tool, providing insights into interchangeability from federal and state perspectives. It is intended to help stakeholders navigate the complexities of biosimilar substitution.

Access the Report

To purchase the report, contact us.

Avalere’s experts in commercialization, regulatory, and policy strategy can help manufacturers, patient advocacy organizations, and other stakeholders analyze the statutes and access implications to biosimilar substitution shift, and help develop strategies to mitigate delays in patient access to biosimilars. This report offers comprehensive analysis along with recently updated state legislation.

 

 

Webinar | A Closer Look at Patient Support Avalere experts explored how potential implications of the Inflation Reduction Act (IRA)’s out-of-pocket cap, in addition to other key regulatory and policy activities shaping benefit design and patient cost-share (e.g., EHB), could impact patient commercial and foundation assistance. Learn More
Watch Now

Sign up to receive more insights about Federal and State Policy
Please enter your email address to be notified when new Federal and State Policy insights are published.

Back To Top